Hepatic gene therapy for haemophilia B

Haemophilia

Volumn 4, Issue 4, 1998, Pages 389-392

  Kay, M A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hepatocyte; Liver; Viral vectors

Indexed keywords

BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD LEVEL; CONFERENCE PAPER; DOG; EXPRESSION VECTOR; GENE THERAPY; HEMOPHILIA B; HEMOSTASIS; IMMUNE RESPONSE; LEUKOCYTE COUNT; LIVER; LIVER CELL; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROVIRUS; SAFETY;

EID: 0031877214     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440389.x     Document Type: Conference Paper

References (20)

1. Armentano D, Thompson G, Darlington G, Woo SL. Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B. Proc Natl Acad Sci USA 1990; 87: 6141-5.
2. Brinkhous KM. Gene transfer in the hemophilias: retrospect and prospect. Thromb Res 1992; 67: 329-38.
3. Brownlee GG. Prospects for gene therapy of haemophilia A and B. Br Med Bull 1995; 51: 91-105.
4. Dai YF, Qiu XF, Xue JL, Liu ZD. High efficient transfer and expression of human clotting factor IX cDNA in cultured human primary skin fibroblasts from hemophilia B patient by retroviral vectors. Sci China B 1992; 35: 183-93.
5. Thompson AR, Palmer TD, Lynch CM, Miller AD. Gene transfer as an approach to cure patients with hemophilia A or B. Curr Stud Hematol Blood Transfus 1991; 58: 59-62.
6. Kay MA, Baley P, Rothenberg S, Leland F, Fleming L, Ponder KP et al. Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sci USA 1992; 89: 89-93.
7. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
8. Wang L, Zoppe M, Hackeng TM, Griffin JH, Lee KF, Verma IM. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci USA 1997; 94: 11563-6.
9. Kay MA, Li Q, Liu TJ, Leland F, Toman C, Finegold M, Woo SL. Hepatic gene therapy: persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. Hum Gene Ther 1992; 3: 641-7.
10. Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs [see comments]. Science 1993; 262: 117-9.
11. Evans JPK, Brinkhous M, Brayer GD, Reisner HM, High KA. Proc Natl Acad Sci USA 1992; 86: 10095-9.
12. Lieber A, Vrancken Peeters MJTFD, Gown A, Perkins J, Kay MA. A modified urokinase plasminogen activator induces liver regeneration without bleeding. Hum Gene Ther 1995; 6.
13. Lieber A, Vrancken Peeters MJTFD, Meuse L, Fausto N, Perkins J, Kay MA. Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo. Proc Natl Acad Sci USA 1995; 92: 6210-4.
14. Bosch A, McCray PB-J, Chang SM, Ulich TR, Simonet WS, Jolly DJ, Davidson BL. Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes. J Clin Invest 1996; 98: 2683-7.
15. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genetics 1997; 17: 314-7.
16. Li Q, Kay MA, Finegold M, Stratford Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4: 403-9.
17. Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sei USA 1994; 91: 2353-7.
18. Kay MA, Holterman A-X, Meuse L, Gown A, Ochs H, Linsley PS, Wilson CB. Long-term hepatic adenovirus mediated gene expression in mice following CTLA4Ig administration. Nature Genetics 1995; 11: 191-7.
19. Kay MA, Meuse L, Gown AM, Linsley P, Hollenbaugh D, Aruffo A, et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus. Proc Natl Acad Sci USA 1996; 94: 4686-91.
20. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genetics 1996; 16: 270-6.